Best Compounded Semaglutide Telehealth Providers 2026: Honest Comparison

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

The compounded semaglutide telehealth market in 2026 looks different than it did eighteen months ago. The FDA officially declared the semaglutide shortage resolved in February 2025, which removed the regulatory pathway that allowed large 503B outsourcing facilities to mass-produce semaglutide copies for telehealth distribution. What remains is patient-specific compounding at 503A pharmacies for clinically justified situations, which has reshaped how the major providers operate, what they charge, and what they tell patients about long-term supply.

This page is a side-by-side comparison of the providers most patients are evaluating: Hims, Henry Meds, Mochi Health, Eden, Lavender Sky Health, Ivim Health, ShedRx, Skinny Rx, Ro, and HealthRX. The goal is not to rank them. The goal is to lay out pricing, sourcing, clinical structure, and patient experience in a format that lets a reader compare the same fields across providers. Everything below is drawn from public pricing pages, terms of service, FDA correspondence, court filings, and third-party reviews collected in early 2026.

For background on what compounded semaglutide is and how the regulatory framework works, see the pillar guide.

The 2026 Regulatory Backdrop

Three events from late 2024 and 2025 frame how to read any provider's current offering.

First, the FDA declared the semaglutide shortage resolved on February 21, 2025. Under section 503A of the Federal Food, Drug, and Cosmetic Act, 503A pharmacies may still compound semaglutide for an individual patient when there is a documented clinical reason that the commercial product does not meet that patient's needs. What is no longer permitted is large-scale 503B production based on a shortage designation. Most major telehealth providers transitioned to a "personalized formulation" model in 2025, typically combining semaglutide with B12, glycine, or another additive, which keeps the prescription inside the 503A clinical-need exception.

Second, the FDA issued a warning letter to Hims & Hers Health on September 22, 2025, citing concerns about marketing claims that compared the compounded product to FDA-approved Wegovy and Ozempic in ways the agency considered misleading. Hims responded by adjusting marketing language and continued operations. The warning letter is public on the FDA website.

Third, Novo Nordisk filed civil suits in 2024 and 2025 against several telehealth and compounding companies, alleging the use of "inauthentic" semaglutide active pharmaceutical ingredient, meaning API sourced from manufacturers that Novo Nordisk did not authorize. Several suits were settled or dismissed; others remain active. Public court records list the specific defendants. A patient evaluating a provider in 2026 should ask which pharmacy supplies the API and whether that pharmacy can document its source.

These three facts do not make any specific provider unsafe. They do mean that the questions a patient asks in 2026 are different from the questions they would have asked in 2023.

The Comparison Fields

The fields below are the ones we have found most predictive of patient experience after working with thousands of patients who came from other providers.

Price per month, flat-rate or escalating. A meaningful number of providers price month one differently from month two, or escalate price as the dose escalates. Flat-rate pricing across the full titration is the exception.

Pharmacy type and disclosure. 503A versus 503B, named or unnamed, in-state or out-of-state. A provider that will tell the patient which pharmacy is filling their prescription is a better-than-average provider.

Clinician access model. Asynchronous messaging only, async plus video on request, or video by default. Whether clinical questions cost extra after the initial visit.

Cancellation terms. Month-to-month with cancel anytime, or multi-month commitment with prepayment.

LegitScript status. Certified, not certified, or claimed-but-unverifiable.

State coverage. Most providers operate in 40 to 50 states. A few do not, and a few have state-specific carve-outs.

Formulation. Plain semaglutide, semaglutide-with-B12, semaglutide-with-glycine, or oral preparations. The additive often determines whether the prescription is defensible under the 503A clinical-need standard.

Hims Semaglutide

Hims, operating under Hims & Hers Health, launched its compounded semaglutide weight loss program in 2024. The 2026 program offers compounded semaglutide at a list price of $199 per month for an annual commitment, or $299 for month-to-month, with dose-escalation pricing increasing in later months. The provider does not publicly name its compounding pharmacy on the consumer site, though it has disclosed pharmacy partners in regulatory filings.

The September 2025 FDA warning letter cited marketing claims about the compounded product's equivalence to FDA-approved Wegovy and Ozempic. Hims revised marketing language in response. The provider continues to operate and remains LegitScript-certified as of early 2026.

Clinician access is primarily asynchronous through the Hims platform, with video visits available for the initial consult. The provider operates in most states but excludes a handful, including Louisiana and Mississippi at last check. Cancellation is permitted on monthly plans; annual plans require working through customer support and are non-refundable for medication shipped.

For a detailed write-up, see our Hims compounded semaglutide review and our is Hims semaglutide legit breakdown.

Henry Meds Semaglutide

Henry Meds was one of the earliest movers in the compounded GLP-1 telehealth market and built its brand on flat-rate pricing. The 2026 program is $297 per month, flat-rate across all doses, with no annual commitment required. The provider has consistently disclosed its 503A pharmacy partners on request and operates with a named medical director.

The provider has been LegitScript-certified throughout its operating history. State coverage is broad, with active operations in roughly 48 states. Clinician access is asynchronous with a published response-time standard, and a clinical question does not generate an additional fee.

Henry Meds has not been the subject of FDA warning letters or active Novo Nordisk litigation as of early 2026.

For more, see our Henry Meds semaglutide review.

Mochi Health Semaglutide

Mochi Health operates a clinician-network model in which patients are matched with an obesity-medicine-trained physician for ongoing care. The 2026 program is $129 to $279 per month depending on plan and dose, with the lower price points tied to insurance billing for the visit component and the medication paid out of pocket. The provider partners with multiple pharmacies and discloses the pharmacy on request.

The clinical model is a meaningful differentiator. Mochi structures the patient relationship around recurring physician visits, lab monitoring at three and six months, and documented dose-adjustment protocols. The provider operates in roughly 45 states and is LegitScript-certified.

The trade-off for patients is that the clinician-heavy model produces a higher-touch experience and a higher effective cost when the medication is bundled with visits. Patients who want a low-friction medication-only experience often find the structure heavier than they want.

For more, see our Mochi Health semaglutide review.

Eden Semaglutide

Eden offers compounded semaglutide on a month-to-month basis priced at $296 per month flat-rate, with no annual commitment and the same price across the titration schedule. The provider uses 503A pharmacy partners that are disclosed on request and operates in most states.

Clinician access is asynchronous through the Eden platform. The provider does not require a baseline lab panel as a condition of starting therapy, which is a difference from providers that gate initiation on labs. Some patients prefer the lower friction; clinically, baseline labs are the standard practice and patients should consider obtaining them independently if Eden does not require them.

Eden is LegitScript-certified and has not been the subject of an FDA warning letter as of early 2026.

For more, see our Eden semaglutide review.

Lavender Sky Health Semaglutide

Lavender Sky Health is a clinician-led practice rather than a pure telehealth platform, and the program is structured around a longer initial visit, a documented care plan, and quarterly follow-ups. The 2026 program is approximately $299 to $399 per month depending on dose and protocol, with the higher end reflecting compounded semaglutide combined with adjunct medications.

The clinician-led structure means most patients have a named physician or NP throughout therapy, which contrasts with the rotating-clinician model common at larger platforms. The provider discloses its compounding pharmacy and is LegitScript-certified. State coverage is narrower than the largest platforms, covering roughly 35 states.

For more, see our Lavender Sky Health semaglutide overview.

Ivim Health Semaglutide

Ivim Health operates an in-person plus telehealth hybrid in several markets, with the telehealth-only program priced at $259 to $339 per month depending on plan structure. The provider names its compounding pharmacy partners and operates with a named medical director.

The hybrid model is a fit for patients who want telehealth convenience with the option of an in-person visit if needed. State coverage on the telehealth-only program is roughly 40 states; the in-person network is concentrated in the Mountain West and Southeast. Ivim is LegitScript-certified.

For more, see our Ivim Health semaglutide overview.

ShedRx Semaglutide

ShedRx offers compounded semaglutide priced at $249 per month for a six-month commitment, or $279 for month-to-month. The provider uses 503A pharmacy partners and discloses on request. State coverage is broad. The provider is LegitScript-certified.

The clinical model is asynchronous-default with video available for the initial visit. The provider does not require baseline labs for initiation but recommends them.

For more, see our ShedRx and Skinny Rx semaglutide overview.

Skinny Rx Semaglutide

Skinny Rx offers a similar structure to ShedRx with month-to-month pricing in the $269 to $299 range depending on plan. The provider uses 503A pharmacy partners and operates in most states. LegitScript certification status should be verified directly on the LegitScript site at the time of evaluation.

The clinical model is asynchronous through the Skinny Rx platform. The provider's marketing emphasizes rapid onboarding, which is consistent with the asynchronous-first structure.

Ro Semaglutide

Ro, formerly Roman, operates a broad-based telehealth platform of which the weight loss program is one offering. The compounded semaglutide program is part of Ro's Body Program, priced at $99 per month for the program access fee with medication priced separately, producing an effective monthly cost in the $200 to $300 range depending on dose.

The provider's pharmacy partnerships are disclosed on request, and Ro operates with a named medical director and a clinician network. State coverage is broad. The provider is LegitScript-certified.

For more, see our Ro semaglutide review.

HealthRX Semaglutide

HealthRX offers compounded semaglutide at flat-rate pricing of $179.99 to $279.99 per month depending on plan, with the same price across the full titration schedule. The provider uses 503A pharmacy partners that are disclosed on request and operates with a published clinician access standard. Cancellation is month-to-month with no commitment.

HealthRX is LegitScript-certified and operates in 47 states. The provider's editorial position on competing offerings is that flat-rate, transparent pricing is the floor a patient should expect from any provider, and that the comparison work is the patient's right.

Side-by-Side at a Glance

| Provider | Price (monthly) | Flat-rate? | Pharmacy disclosure | Commitment | |---|---|---|---|---| | Hims | $199-$299 | No (escalates) | On request, partial | Annual or monthly | | Henry Meds | $297 | Yes | On request | Month-to-month | | Mochi Health | $129-$279 | No (plan-dependent) | On request | Month-to-month | | Eden | $296 | Yes | On request | Month-to-month | | Lavender Sky | $299-$399 | No | On request | Month-to-month | | Ivim Health | $259-$339 | No | On request | Month-to-month | | ShedRx | $249-$279 | Yes | On request | 6-month or monthly | | Skinny Rx | $269-$299 | Yes | On request | Month-to-month | | Ro | ~$200-$300 effective | No | On request | Month-to-month | | HealthRX | $179.99-$279.99 | Yes | On request | Month-to-month |

Prices are list prices on consumer-facing pages as of early 2026. Effective prices vary with dose, plan, and promotional offers.

How to Use This Comparison

A patient who has narrowed to three or four providers should make a short list of questions and ask each provider the same questions. The useful questions are: Which pharmacy compounds the medication? Is the formulation plain semaglutide or a combination preparation? What is the price in month two and at the highest dose? What happens if I want to cancel after the first shipment? Do I have access to a clinician without an additional fee?

The provider whose answers are the clearest, regardless of who they are, is usually the better fit.

For deeper coverage of any specific provider, follow the supporting article links above. For the evaluation framework that produced the fields in this comparison, see our pillar guide.

For the foundational overview, return to the pillar guide.

Not FDA-approved. HealthRX is not a medical practice. Information on this site is for educational purposes and is not a substitute for individualized medical advice. Treatment decisions are made between you and a licensed clinician. Compounded semaglutide is dispensed by state-licensed 503A pharmacies under individual prescriptions for clinically documented patient-specific need. Pricing, state coverage, and program terms for third-party providers are based on public information available in early 2026 and are subject to change. References: SUSTAIN program, STEP-1 (Wilding et al., NEJM 2021), STEP-3 (Wadden et al., JAMA 2021), STEP-4 (Rubino et al., JAMA 2021), SELECT (Lincoff et al., NEJM 2023); FDA Drug Shortage status update, February 2025; FDA Warning Letter to Hims & Hers Health, September 22, 2025.

This HealthRX guide is educational and is not a prescription, diagnosis, or substitute for care from a licensed clinician. Compounded semaglutide is not FDA-approved. Treatment decisions should be made with a prescriber who has reviewed your medical history.